biologic news from FierceBioResearcher

A new study in mice raises the possibility that humans may one day be able to eat any kind of fat they want without raising their risk of heart disease. The study involved deleting a gene in the mice that causes production of ACAT2, an enzyme that alters the molecular structure of cholesterol so that it can be transported to the body's cells.

"We deleted an enzyme in mice and they could eat any type of fat and not get heart disease," said Lawrence Rudel, Ph.D., a professor of …

Ronald M. Evans, an investigator at The Salk Institute in San Diego, has developed a drug that switches on the PPAR-d gene in mice, protecting them against weight gain from high-calorie and high-fat diets. The drug--which mimics fat--triggers their metabolisms and generates a physical response similar to exercising. After treatment, the mice had lower levels of fatty acids, triglyceride and sugar levels. These mice also exhibited much greater stamina, allowing them to exercise twice as …

Biotech drugs take longer and cost more than the traditional medicines fielded by the FDA, according to a new survey from Tufts University's Center for the Study of Drug Development. On average, a complex biologic costs $1.2 billion to approval over a period of 97.7 months. That's 7.4 months longer and much higher than the $899 million average cost the center figured for traditional meds in 2005. The numbers are likely to be heavily featured in the debate over the retail cost of …